Table 6.
Stratified analysis for CD5/CD43 coexpression and DLBCL patients’ survival
| Risk factor | Event‐free survival | Overall survival | ||
|---|---|---|---|---|
| Adjusted RR (95% CI) | P | Adjusted RR (95% CI) | P | |
| Age | ||||
| ≤60 y | 10.964 (3.458‐34.760) | <0.001 | 12.626 (3.726‐42.783) | <0.001 |
| >60 | 12.125 (4.347‐33.821) | <0.001 | 9.099 (3.307‐25.036) | <0.001 |
| Ann Arbor stage | ||||
| I‐II | 10.566 (3.016‐37.013) | <0.001 | 7.083 (2.048‐24.501) | <0.001 |
| III‐IV | 7.210 (2.897‐17.944) | <0.001 | 8.023 (3.119‐20.635) | <0.001 |
| LDH level | ||||
| Normal | 42.557 (5.871‐308.476) | <0.001 | 10.736 (2.260‐50.992) | <0.001 |
| Evaluated | 4.838 (2.166‐10.806) | <0.001 | 5.644 (2.489‐12.800) | <0.001 |
| Treatment | ||||
| CHOP | 7.656 (2.619‐22.385) | <0.001 | 9.081 (3.065‐26.904) | <0.001 |
| R‐CHOP | 8.280 (3.027‐22.648) | <0.001 | 5.276 (1.969‐14.138) | 0.001 |
CI, confidence interval; RR, relative risk; LDH, lactic dehydrogenase.